RxDoctor Payments DataLook up a doctor →

Kerri Boemio

Family · Island Heights, NJNPI 1427715267

Payments from drug & device makers

$15,342in general payments, 2019–2025

Across 894 payments — averaging $17.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$4K
  • AbbVie$1K
  • Bayer$773
  • GSK$720
  • Regeneron Healthcare Solutions, Inc.$668
  • Corcept Therapeutics$584
  • plus $8K from 50 others

What the payments were for

  • Food & beverage$15,19799%
  • Education$1451%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,342 in reported general payments places this provider in the 95th percentile of 2,692 family providers in New Jersey.

See all family providers in New Jersey

Medicare billing

Part B allowed, 2024
$30,677
Medicare patients
185
Services billed
682

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide111$118,204
IngrezzaValbenazine Tosylate12$86,444
ZenpepLipase/Protease/Amylase12$64,945
VraylarCariprazine Hcl26$58,025
OzempicSemaglutide52$57,519
Dupixent PenDupilumab11$40,312
FarxigaDapagliflozin Propanediol26$36,689
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$32,638
JanuviaSitagliptin Phosphate21$23,453
EliquisApixaban28$20,887
MyrbetriqMirabegron22$17,676
TrulicityDulaglutide11$17,172
TrintellixVortioxetine Hydrobromide27$14,923
Breo ElliptaFluticasone/Vilanterol16$8,591
AirsupraAlbuterol Sulfate/Budesonide11$4,990

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$519$135,376122 claims
Aimmune Therapeutics, Inc.Zenpep$147$64,94512 claims
AbbVieVraylar, Synthroid$1,427$59,19946 claims
Novo NordiskOzempic$185$57,51952 claims
AstraZenecaFarxiga, Airsupra$3,557$41,67937 claims
GSKTrelegy Ellipta, Breo Ellipta$720$41,22854 claims
MerckJanuvia$369$23,45321 claims
PfizerEliquis$356$20,88728 claims
Astellas Pharma US IncMyrbetriq$84$17,67622 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$142$14,92327 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,692 family providers in New Jersey.

Other family in Island Heights

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →